Effect of glycemic treatment and microvascular complications on menopause in women with type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort

Catherine Kim, Patricia A Cleary, Catherine C Cowie, Barbara H Braffett, Rodney L Dunn, Mary E Larkin, Patricia M Gatcomb, Hunter B Wessells, David M Nathan, Aruna V Sarma, DCCT/EDIC Research Group, Catherine Kim, Patricia A Cleary, Catherine C Cowie, Barbara H Braffett, Rodney L Dunn, Mary E Larkin, Patricia M Gatcomb, Hunter B Wessells, David M Nathan, Aruna V Sarma, DCCT/EDIC Research Group

Abstract

OBJECTIVE We examined the impact of intensive versus conventional diabetes treatment upon menopause among women with type 1 diabetes in the Diabetes Control and Complications Trial (DCCT), a randomized controlled trial of intensive diabetes treatment, and its observational follow-up, the Epidemiology of Diabetes Interventions and Complications (EDIC) study. RESEARCH DESIGN AND METHODS In a secondary analysis of women in the DCCT/EDIC (n = 657), outcomes were the cumulative incidences of natural menopause and surgical menopause. Cox regression analyses were used to examine associations with treatment group, time-varying estimates of hemoglobin A1c (HbA1c), insulin dosage, BMI, and microvascular complications (retinopathy, nephropathy, and neuropathy). RESULTS By EDIC year 18, after an average of 28 years of follow-up, 240 (38%) women had experienced natural menopause and 115 (18%) women had experienced surgical menopause. Age at natural menopause was similar in the intensive versus conventional groups (49.9 vs. 49.0 years; P = 0.28), and age at surgical menopause was similar in the intensive versus conventional groups (40.8 vs. 42.0 years; P = 0.31). In multivariable models, treatment group, HbA1c, and microvascular complications were not associated with risk of natural or surgical menopause. Each 10 unit/day increase in insulin dosage decreased risk of natural menopause (hazard ratio [HR] 0.91, 95% CI 0.75-0.98) and each kg/m(2) increase in BMI increased risk of surgical menopause (HR 1.08, 95% CI 1.00-1.16). CONCLUSIONS In the DCCT/EDIC, intensive versus conventional treatment group and HbA1c level were not associated with menopause risk. Greater insulin dose was associated with lower menopause risk.

Trial registration: ClinicalTrials.gov NCT00360815 NCT00360893.

Figures

Figure 1
Figure 1
Flow of female participants through the DCCT/EDIC studies.
Figure 2
Figure 2
Cumulative incidence of natural menopause and surgical menopause by DCCT/EDIC treatment group. At time zero (DCCT baseline), the mean age of the female cohort was 26 years (range 13–39). After an average of 25 years of DCCT/EDIC follow-up, 240 women had reached natural menopause (2% during the DCCT and 98% during EDIC) and 115 women underwent surgical menopause (20% during the DCCT and 80% during EDIC). The mean ages at natural menopause and surgical menopause were 49.6 ± 4.4 and 41.4 ± 6.7 years, respectively.

References

    1. Dorman JS, Steenkiste AR, Foley TP, et al. Familial Autoimmune and Diabetes (FAD) Study Menopause in type 1 diabetic women: is it premature? Diabetes 2001;50:1857–1862
    1. Snell-Bergeon JK, Dabelea D, Ogden LG, et al. Reproductive history and hormonal birth control use are associated with coronary calcium progression in women with type 1 diabetes mellitus. J Clin Endocrinol Metab 2008;93:2142–2148
    1. Bakalov VK, Anasti JN, Calis KA, et al. Autoimmune oophoritis as a mechanism of follicular dysfunction in women with 46,XX spontaneous premature ovarian failure. Fertil Steril 2005;84:958–965
    1. Hoek A, Schoemaker J, Drexhage HA. Premature ovarian failure and ovarian autoimmunity. Endocr Rev 1997;18:107–134
    1. Betterle C, Rossi A, Dalla Pria S, et al. Premature ovarian failure: autoimmunity and natural history. Clin Endocrinol (Oxf) 1993;39:35–43
    1. Tatone C, Carbone MC, Campanella G, et al. Female reproductive dysfunction during ageing: role of methylglyoxal in the formation of advanced glycation endproducts in ovaries of reproductively-aged mice. J Biol Regul Homeost Agents 2010;24:63–72
    1. Sjöberg L, Pitkäniemi J, Harjutsalo V, et al. Menopause in women with type 1 diabetes. Menopause 2011;18:158–163
    1. Gaete X, Vivanco M, Eyzaguirre FC, et al. Menstrual cycle irregularities and their relationship with HbA1c and insulin dose in adolescents with type 1 diabetes mellitus. Fertil Steril 2010;94:1822–1826
    1. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000;342:381–389
    1. Steffes M, Cleary P, Goldstein D, et al. Hemoglobin A1c measurements over nearly two decades: sustaining comparable values throughout the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications study. Clin Chem 2005;51:753–758
    1. de Boer IH, Sun W, Cleary PA, et al. ; DCCT/ EDIC Research Group Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011;365:2366–2376
    1. Albers J, Herman W, Pop-Busui R, et al. Effect of prior intensive insulin treatment during the DCCT on peripheral neuropathy in type 1 diabetes during the EDIC Study. Diabetes Care 2010;33:1090–1096
    1. Prentice RL, Kalbfleisch JD, Peterson AV, Jr, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics 1978;34:541–554
    1. Isik S, Ozcan HN, Ozuguz U, et al. Evaluation of ovarian reserve based on hormonal parameters, ovarian volume, and antral follicle count in women with type 2 diabetes mellitus. J Clin Endocrinol Metab 2012;97:261–269
    1. Codner E, Iñiguez G, Hernández IM, et al. Elevated anti-Müllerian hormone (AMH) and inhibin B levels in prepubertal girls with type 1 diabetes mellitus. Clin Endocrinol (Oxf) 2011;74:73–78
    1. Lepine LA, Hillis SD, Marchbanks PA, et al. Hysterectomy surveillance United States, 1980–1993. MMWR CDC Surveill Summ 1997;46:1–15
    1. Cooper R, Hardy R, Kuh D. Is adiposity across life associated with subsequent hysterectomy risk? Findings from the 1946 British birth cohort study. BJOG 2008 Jan;115(2):184–192;discussion 192
    1. Whiteman M, Hillis S, Jamieson D, et al. Inpatient hysterectomy surveillance in the United States, 2000-2004. Am J Obstet Gynecol 2008;198:34.e1–34.e7
    1. Gold EB, Bromberger J, Crawford S, et al. Factors associated with age at natural menopause in a multiethnic sample of midlife women. Am J Epidemiol 2001;153:865–874
    1. Soto N, Iñiguez G, López P, et al. Anti-Mullerian hormone and inhibin B levels as markers of premature ovarian aging and transition to menopause in type 1 diabetes mellitus. Hum Reprod 2009;24:2838–2844

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi